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Small molecule inhibitor of OGG1 
blocks oxidative DNA damage 
repair at telomeres and potentiates 
methotrexate anticancer effects
Juan Miguel Baquero1,9, Carlos Benítez‑Buelga2,9*, Varshni Rajagopal2, Zhao Zhenjun2, 
Raúl Torres‑Ruiz3,4, Sarah Müller2, Bishoy M. F. Hanna2, Olga Loseva2, Olov Wallner2, 
Maurice Michel2, Sandra Rodríguez‑Perales3, Helge Gad5, Torkild Visnes6, 
Thomas Helleday2,5, Javier Benítez1,7,8 & Ana Osorio1,7*
The most common oxidative DNA lesion is 8‑oxoguanine which is mainly recognized and excised by 
the 8‑oxoG DNA glycosylase 1 (OGG1), initiating the base excision repair (BER) pathway. Telomeres 
are particularly sensitive to oxidative stress (OS) which disrupts telomere homeostasis triggering 
genome instability. In the present study, we have investigated the effects of inactivating BER in OS 
conditions, by using a specific inhibitor of OGG1 (TH5487). We have found that in OS conditions, 
TH5487 blocks BER initiation at telomeres causing an accumulation of oxidized bases, that is 
correlated with telomere losses, micronuclei formation and mild proliferation defects. Moreover, 
the antimetabolite methotrexate synergizes with TH5487 through induction of intracellular reactive 
oxygen species (ROS) formation, which potentiates TH5487‑mediated telomere and genome 
instability. Our findings demonstrate that OGG1 is required to protect telomeres from OS and present 
OGG1 inhibitors as a tool to induce oxidative DNA damage at telomeres, with the potential for 
developing new combination therapies for cancer treatment.
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53BP1  P53-binding protein 1
8-oxoG  8-Oxoguanine
ALT  Alternative lengthening of telomeres
APE1i  Apurinic/apyrimidinic endonuclease 1 inhibitor
BER  Base excision repair
BSA  Bovine serum albumin
ChIP  Chromatin Immunoprecipitation
DAPI  4′,6-Diamidino-2-phenylindole
DCF  2′,7′-Dichlorofluorescein
DDR  DNA damage response
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DMSO  Dimethyl sulfoxide
DSB  Double-strand break
EDTA  Ethylenediaminetetraacetic acid
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GFP  Green fluorescent protein
H2AX  H2A histone family member X
H2DCFDA  2′,7′-Dichlorodihydrofluorescein diacetate
IF  Immunofluorescence
IgG-HRP  Immunoglobulin G horseradish peroxidase
KO  Knockout
LIG3  DNA ligase III
MOI  Multiplicity of infection
NT  Non-targeting
OGG1  8-OxoG DNA glycosylase 1
OS  Oxidative stress
PARPi  Poly ADP ribose polymerase inhibitor
PBS  Phosphate buffered saline
PFA  Paraformaldehyde
PVDF  Polyvinylidene difluoride
PNA  Peptide nucleic acid
POLB  Polymerase beta
qPCR  Quantitative polymerase chain reaction
RIPA  Radioimmunoprecipitation assay
ROS  Reactive oxygen species
SDS-PAGE  Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
SEM  Standard error of the mean
SSB  Single-strand break
SSC  Saline-sodium citrate
STR  Short tandem repeat
TBS-T  Tris buffered saline with Tween-20
Telo-FISH  Fluorescence in situ hybridization
TIF  Telomere dysfunction-induced foci
TNF  Tumor necrosis factor
TRF2  Telomeric repeat-binding factor 2
XRCC1  X-ray repair cross-complementing 1
ZIP  Zero interaction potency
Telomeres are nucleoprotein structures that protect the ends of linear eukaryotic chromosomes. In humans, 
telomeric DNA is usually of 10–15 kb in length, and is composed of tandemly 5′-(TTA GGG ) n-3′ hexanucleotide 
repeats that are coated by the telomere shelterin  complex1,2. Functional telomeres maintain genome stability by 
preventing chromosomal ends from being recognized as DNA strand  breaks3. On the other hand, dysfunctional 
telomeres, arising from the loss of telomeric repeats and/or sheltering protection, are recognized by many DNA 
damage response proteins, including the phosphorylated H2A histone family member X at serine 139 (γH2AX) 
or the p53-binding protein 1 (53BP1), that form telomere dysfunction-induced foci (TIF) and lead to genomic 
instability, cell proliferation defects or  apoptosis4,5. Cancer cells are characterized by preserving stable telomere 
length, thereby conferring cell  immortality6. In consequence, the induction of telomeric instability is considered 
as a potential therapeutic strategy for cancer  treatment7.
Oxidative DNA damage is generated by reactive oxygen species (ROS) and constitutes the majority of DNA 
damage in human  cells8. Several lines of evidence indicate that telomeres are particularly sensitive to oxidative 
stress (OS)9,10. Considering that guanine has the lowest redox potential among canonical nucleobases, the high 
incidence of these residues in the telomeric DNA sequence makes telomeres a potential hotspot for oxidative 
DNA  damage11. In OS conditions, 8-oxoguanine (8-oxoG) is the most common base lesion, and can be converted 
into single or double-strand breaks (SSBs or DSBs), if it is not repaired correctly, or can be mutagenic by GC:TA 
 transversions12. At telomeres, 8-oxoG decreases the binding of the shelterin  complex13,14, potentially leading to 
telomere shortening, uncapping and finally telomere  crisis14–16. This is a cellular state characterized by extensive 
genomic instability, including translocations, amplifications, and deletions related to aging-induced processes 
and  cancer17.
The Base Excision Repair (BER) pathway is the main responsible for removing oxidized nucleotides from 
DNA, and it is active at  telomeres18,19. BER can be initiated by eleven different DNA glycosylases that recognize 
and excise specific base lesions. In the case of BER initiation due to 8-oxoG excision by 8-oxoG DNA glycosylase 
1 (OGG1), the resulting abasic sites are cleaved by an apurinic/apyrimidinic endonuclease (APE1), that gener-
ates a nucleotide gap containing a 3′-hydroxyl end. In short-patch BER the nucleotide gap is filled up with the 
correct nucleotide by polymerase β (POLB) and sealed by DNA ligase III (LIG3), in a process mediated by the 
scaffold protein X-ray repair cross-complementing 1 (XRCC1)20,21. In human cells, 8-oxoG is mainly excised by 
OGG1, which removes 8-oxoG opposite cytosine in double-stranded DNA. This enzyme is necessary to preserve 
telomere integrity, especially under OS  conditions14,16,22.
Fouquerel et al.16 have recently proven that acute 8-oxoG telomeric formation in cells lacking functional 
OGG1 leads to telomere fragility, while a chronic 8-oxoG exposure results in telomere shortening, replication 
stress at telomeres, telomere losses and postmitotic defects such as micronuclei formation, anaphase bridge 
formation, chromosome fusions and proliferation  defects16.
The recently developed OGG1 inhibitor TH5487 has proved to bind efficiently to the catalytic site of OGG1 
blocking its enzymatic  activity23,24. Cultured cells treated with TH5487 are more sensitive to OS  conditions23. 
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:3490  | https://doi.org/10.1038/s41598-021-82917-7
www.nature.com/scientificreports/
Surprisingly, the absolute levels of genomic 8-oxoG remain low after TH5487  treatment25, however its impact 
on specific genome locations enriched in 8-oxoG has not been studied. We hypothesize that OGG1 inhibition 
may recapitulate the phenotypic telomeric defects previously observed in OGG1 depleted  cells16, representing an 
attractive and unexplored opportunity for compromising telomere integrity in cells exposed to high ROS levels. 
Furthermore, OGG1 inhibitors may potentiate the telomere instability associated with conventional chemo-
therapeutic agents, increasing their therapeutic effect.
In the present study, we characterize temporal-space OGG1 DNA repair activity at telomeres of cancer 
cells during basal and OS conditions. Secondly, we explore whether OGG1 inhibition can interfere with BER 
activation at telomeres and characterize the telomere and cellular defects associated with OGG1 inhibition or 
depletion. Finally, we perform a screening of conventional chemotherapeutic agents that might synergize with 
OGG1 inhibitors contributing to telomere or genome instability.
Results
Telomeres are a hotspot for oxidation due to cell cycle ROS production. We used the U2OS oste-
osarcoma cell line, a well-established model in telomere  biology26, for most experiments presented in this study. 
By using a modified version of the procedure described by O’Callaghan et al.27, we measured by qPCR oxidative 
DNA damage at telomeric DNA or the 36B4 locus, whose amplified regions contain a similar percentage of G:C 
base pairs (50% telomeres vs 52% 36B4). In basal conditions, we found that U2OS cells accumulate higher levels 
of oxidized bases at telomeres compared to 36B4 locus (Fig. 1A). Complementary, chromatin immunoprecipita-
tion (ChIP) coupled to telomere PCR showed that OGG1 was significantly enriched at telomeres compared to 
the genomic region 36B4 in basal conditions (Fig. 1B). Then, we measured oxidized bases levels in DNA from 
cells sorted by cell cycle phase. In both genomic regions, the highest level of oxidative DNA damage was detected 
in the S phase (Fig. 1C). The highest relative levels of telomeric oxidized bases between telomeres and the 36B4 
locus (ΔCt ratio telomeres/36B4) were found during the G2/M phase (Supplementary Figure S1C).
Interestingly, OGG1 protein levels remained constant throughout the cell cycle in U2OS cells (Fig. 1D). In 
contrast, when we measured intracellular ROS production, we observed that in the transition from G1 to S phase, 
endogenous ROS levels increased until reaching maximum values during G2/M (Fig. 1E), coinciding with the 
highest relative level of oxidized bases detected at telomeres. These results suggest that oxidative DNA damage 
generated by endogenous ROS might be progressively accumulated in telomeres throughout the cell cycle.
OGG1 initiates BER at telomeres upon OS. In order to generate OS conditions, U2OS cells were 
exposed to  H2O2 treatment (200  µM/1  h). This treatment significantly increased oxidative lesions at telom-
eric DNA (Supplementary Figure S3A), demonstrating its efficacy. However, we measured OGG1 protein levels 
(Supplementary Figure S3B) under OS conditions, and no significant differences were detected compared to 
untreated cells.
Confocal microscopy in U2OS cells expressing OGG1 fused to green fluorescent protein (GFP; OGG1-GFP) 
was used to track whether OGG1 was recruited to damaged DNA after OS treatment. First, we removed the 
chromatin-unbound OGG1-GFP by using a pre-extraction step before fixation. Nuclear patches were detected 
only in cells exposed to OS, while in non-treated cells all the OGG1-GFP signal was removed (Supplementary 
Figures S3C and S3D). This result reflects the OGG1 recruitment to chromatin in response to oxidative DNA 
damage. Interestingly, suspension of OS treatment followed by a recovery period (fresh medium/1 h), caused a 
reduction in the levels of oxidized bases at telomeres (Supplementary Figure S3A), together with a significant 
decrease in OGG1-GFP recruitment to the DNA (Supplementary Figures S3C and S3D), evidencing the repair of 
oxidative lesions by BER. Furthermore, we measured by immunofluorescence (IF) OGG1-GFP and XRCC1 signal 
intensity within Telomeric Repeat-binding Factor 2 (TRF2) foci (Supplementary Figures S3E–S3H). OS treat-
ment significantly increases OGG1 and XRCC1 at TRF2 foci, providing evidence of BER activation at telomeres.
Pharmacological OGG1 inhibition disrupts BER at telomeres upon OS. The novel OGG1 inhibi-
tor TH5487 has been reported to bind the active site of OGG1, blocking any potential interaction with its natural 
substrate (8-oxoG) in  DNA23. After showing that OGG1 is required to initiate BER at telomeres, we evaluated 
whether pharmacological inactivation of OGG1 using TH5487 may block BER at telomeres. Firstly, we con-
firmed that TH5487 engaged OGG1 in U2OS cells by thermal shift assay (Supplementary Figure S4A). Next, we 
challenged U2OS cells with TH5487 (10 µM) and measured every 24 h for 4 days the level of oxidized bases at 
telomeres. We found that TH5487 led to a slow and progressive accumulation of oxidized bases (Supplementary 
Figure S4B), likely derived from the ability of TH5487 to preclude OGG1 binding to the damaged telomeres 
(Supplementary Figure S4C).
Complementary, U2OS OGG1-GFP cells were used to generate a knockout (KO) for the OGG1 gene by 
CRISPR/Cas9 (OGG1-KO, see material and methods). OGG1-KO efficacy was validated by fluorescence micros-
copy and immunoblotting (Supplementary Figures S4D and S4E). OGG1-KO U2OS cells were used to compare 
the effects between OGG1 depletion and inhibition with TH5487 at telomeres. Similarly to the treatment with 
the OGG1 inhibitor, OGG1-KO cells showed increased levels of oxidized bases at basal conditions at telomeres 
or 36B4 locus compared to U2OS parental cells (Supplementary Figure S4F).
Additionally, we evaluated by IF the ability of TH5487 to inhibit BER at telomeres. Both in basal and upon 
OS treatment, OGG1 inhibition (TH5487) or depletion (OGG1-KO cells) resulted in a decrease of XRCC1 signal 
intensity at the telomere (Fig. 2A,B), which reflects BER disruption at this specific region. In order to determine 
the consequences of BER impairment, we measured in these cells the levels of oxidized bases at telomeric DNA 
by qPCR compared to the OGG1 proficient cells. We confirmed that OGG1 depletion resulted in a higher accu-
mulation of oxidative DNA damage at telomeres, particularly exacerbated upon OS (Fig. 2C). Furthermore, a 
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recovery period (fresh medium/1 h) after OS treatment, which is coupled to a decrease in oxidative base lesions 
at telomeric DNA from U2OS proficient cells, did not alleviate oxidative DNA damage accumulation for OGG1-
KO cells or OGG1 proficient cells treated with TH5487. Besides, unlike in the case of OGG1-proficient cells, the 
treatment with TH5487 did not increase oxidized base lesions in OGG1-KO cells, ruling out the possibility for 
off-target effects of TH5487 at the telomeric DNA (Fig. 2C).
Finally, we measured the overlapping index of DNA damage markers γH2AX and 53BP1 with TRF2 (tel-
omere) by IF. We established two different OS conditions in the presence or absence of TH5487. For γH2AX we 
exposed cells to OS  (H2O2 200 µM/1 h), while in the case of 53BP1 after an initial pulse of OS  (H2O2 200 µM/1 h), 
we allowed cells to recover for 16 h since unrepaired SSBs generated via BER can be converted into DSBs after 
DNA  replication28. Upon oxidative conditions, we found a significant increase in the overlapping index of both 
γH2AX and 53BP1 foci with telomere TRF2 foci. However, no significant differences were detected regarding 
OGG1 inhibition/depletion in basal or under OS conditions (Supplementary Figure S5).
Pharmacological OGG1 inhibition results in telomere losses and post‑mitotic defects. To 
study the consequences of BER disruption at telomeres by OGG1 inhibition, we examined by telomere fluores-
Figure 1.  Telomeres are a hotspot for oxidation due to cell cycle ROS production. (A) DNA from U2OS cells 
was used to measure 8-oxoG levels at the 36B4 locus or telomeric DNA. Bars show the mean and the standard 
error of the mean (SEM) from 3 technical replicates from 6 independent experiments for each condition 
(Mann–Whitney test; **P < 0.01). (B) OGG1-GFP pulldown followed by chromatin immunoprecipitation 
coupled to PCR for amplification of either 36B4 locus or the telomere regions in the U2OS parental and U2OS 
OGG1-GFP cell lines. Data are the average of 3 technical replicates from 2 independent experiments. Statistical 
significance was determined using (Mann–Whitney test; **P < 0.01. (C) Sorted DNA from different cell cycle 
phases (G1, S, or G2/M) from U2OS cells was used to evaluate 8-oxoG levels at the 36B4 locus or telomeric 
DNA along the cell cycle. Bars show the mean and the SEM from 3 technical replicates from 6 independent 
experiments for each condition (two-sided T-test; *** P < 0.001). (D) Quantification of OGG1 protein expression 
level in U2OS cells along the cell cycle. Actin levels were used to normalize for protein loading. Immunoblotting 
was performed in triplicate. Statistical significance was determined by two-sided T-test (P > 0.05, ns: not 
significant). The full-length blots are presented in Supplementary Figure S2 (E) Percentage of cells with 
intracellular ROS levels above the median of the whole U2OS population is represented in different cell cycle 
stages (G1, S, or G2/M). Data are average ± SEM from single measures from 3 independent experiments. 
Significant differences were addressed by two-sided T-test (P > 0.05, ns: not significant).
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cence in situ hybridization (Telo-FISH) whether TH5487 compromised telomere integrity, or led to post-mitotic 
abnormalities affecting cell proliferation. Analysis of metaphase chromosomes from U2OS OGG1-GFP cells 
revealed that 24 h of exposure to TH5487 in U2OS was enough to observe a significant increase in telomere 
losses (signal-free ends) compared to the control treatment with dimethyl sulfoxide (DMSO). Similarly, OGG1-
KO cells presented a higher number of telomere losses than OGG1-GFP cells while TH5487 treatment did not 
cause additional telomere losses in OGG1-KO cells, excluding off-target effects (Fig. 3A,B). On the contrary, 
we did not observe significant differences in telomere fragility (multi-telomeric signal) after OGG1 depletion 
or inhibition at basal conditions (Fig.  3A,C). Upon OS treatment, we observed a significant increase in the 
frequency of chromosomes with multi-telomeric signals in both groups regardless of the OGG1 status, and no 
additional effect on telomere losses (Supplementary Figures S6A and S6B). These results suggest that telomere 
losses might be associated with OGG1 deficiency, while telomere fragility is a general phenotype occurring in 
OS conditions.
It has been previously reported that the accumulation of oxidative DNA damage induces replication stress at 
telomeres leading to post-mitotic defects, especially when OGG1 is knocked  down16. Here, we measured micro-
nuclei and chromosome bridge formation to evaluate whether exposure to OS in OGG1 depleted or inhibited 
cells have effects on genomic stability. We found that OS caused a significant formation of micronuclei in both 
OGG1 proficient and deficient cells (Fig. 3D). Interestingly, OGG1-KO cells or OGG1 proficient cells treated 
Figure 2.  Pharmacological OGG1 inhibition disrupts BER at telomeres upon OS. (A) Confocal imaging 
of XRCC1 (red) and TRF2 (green) by IF using specific antibodies. DAPI was used to stain the cell nucleus 
(blue). (B) Quantification of XRCC1 signal intensity integrated within telomeres from more than 200 foci 
per condition. Data represent average with SEM from 2 independent experiments (Mann–Whitney test; **** 
P < 0.0001). (C) Relative level of oxidized bases at telomeres in OGG1 inhibited/depleted U2OS cells upon OS 
treatment  (H2O2 200 µM/1 h) or followed by a recovery period (fresh media/1 h). Bars show the mean and 
the SEM from 3 technical replicates from 6 independent experiments for each condition (two-sided T-test; *** 
P < 0.001, ns: not significant).
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with TH5487 presented a significantly higher frequency of micronuclei regardless of OS conditions. In contrast, 
we were not able to find enough chromosome bridges to make a comparative analysis and, only in OGG1-KO 
cells, we could find them at a very low frequency (0.007).
Finally, we evaluated whether OGG1 inhibition or depletion impaired clonogenic potential in U2OS cells. 
No effect due to the OGG1 status was detected (Supplementary Figure S6C), reflecting that OGG1 inhibition/
depletion is not enough to arrest cell proliferation in U2OS cells. Nevertheless, we found that when we inflicted 
OS conditions transiently during colony formation  (H2O2 200 µM/1 h 6 days after seeding), OGG1 inhibition 
in combination with OS lead to the formation of smaller colonies compared to OGG1 proficient U2OS cells 
(P = 0.06), a phenotype that was significantly more pronounced in the OGG1-KO cells (Fig. 3E). These results 
indicate that upon OS conditions, OGG1 inhibition/depletion may lead to proliferation defects.
Figure 3.  Pharmacological OGG1 inhibition results in telomere losses and post-mitotic defects. (A) 
Representative Telo-FISH images of an unaltered chromosome in metaphase stained with DAPI (in blue) with 
the corresponding telomeric signals (in green) at the end of each chromatid. Below, Representative Telo-
FISH images of altered chromosomes showing telomere signal loss in one of the chromatids, multi-telomeric 
signals, and a micronucleus (orange arrows). (B) Quantification of telomeric signal-free ends for the indicated 
conditions in U2OS OGG1-GFP or OGG1-KO cells. Bars show the mean and the SEM for frequency events/
metaphase (30 to 35 metaphases per condition from 2 independent experiments). Statistical significance was 
determined using unpaired, two-sided T-tests (**P < 0.01, ***P < 0.001 and ns: not significant). (C) Comparative 
analysis of the frequency of multi-telomeric signals for the indicated conditions in U2OS OGG1-GFP or 
OGG1-KO cells. Bars show the mean and the SEM for frequency events/metaphase (30 to 35 metaphases per 
condition from 2 independent experiments). Statistical significance was determined using unpaired, two-sided 
T-tests (P > 0.05, ns: not significant). (D) Comparative analysis of micronuclei formation frequency for U2OS 
OGG1-GFP incubated with DMSO or TH5487 and for OGG1-KO at basal conditions or during OS. More than 
200 cells per condition were analyzed. Data is the average of 2 independent experiments. Significant differences 
were calculated using the Mann–Whitney test for non-parametric distributions (**P < 0.01, ***P < 0.001, **** 
P < 0.0001). (E) Up, comparative analysis for the colony area generated in each condition. Significant differences 
were calculated using the Mann–Whitney test for non-parametric distributions (**** P < 0.0001). Down, 
summary for the schedule of treatment to evaluate a specific clonogenic potential feature (area of colonies). Data 
are average of the mean colony area values of a single experiment.
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TH5487 synergizes with conventional anticancer drugs through induction of intracellular 
ROS, telomere DNA damage, and genome instability. We carried out a screening searching for 
potential synergies between OGG1 inhibitors and conventional chemotherapeutic drugs (cisplatin, 5-Fluoracil, 
doxorubicin, methotrexate) or other BER inhibitors (olaparib, APE1i) which might potentiate some of the phe-
notypes described for TH5487 alone with an impact on cell viability for different human cell lines (U2OS, BJ-
TERT, NTUB1, and HCT116).
First, we tested the effect on viability of different drug combinations during 72 h in the different cell lines and 
calculated synergy scores (Table 1). We found that for all the drugs tested, methotrexate was the only compound 
that in combination with TH5487 presented a Z-score indicative of true synergy (Z-Score > 10, https ://syner gyfin 
der.fimm.fi/) for all tested cell lines (Table 1).
Next, based on the synergy maps generated with the viability data (Supplementary Figure S7), we selected 
sublethal doses within the synergy area for TH5487 (5–10 µM), and methotrexate (10 µM) to evaluate the effect 
of each drug individually or in combination, on intracellular ROS generation, micronuclei formation, and 53BP1 
foci overlapping index with TRF2 (telomeres). We first measured the intracellular ROS generated after 72 h of 
exposure to methotrexate alone, or in combination with TH5487 in four different cell lines (Fig. 4). Intracellular 
ROS formation by TH5487 was cell line-specific. In contrast, methotrexate induced intracellular ROS forma-
tion was detected in all cell lines tested at different levels. In combination with TH5487, only in NTUB1 and in 
HCT116 cell lines an additive interaction for intracellular ROS formation was detected (Fig. 4).
Next, we tested whether methotrexate alone or in combination with TH5487 could induce 53BP1-TIF or 
micronuclei formation in U2OS, BJ-TERT, and NTUB1. We excluded from the analysis HCT116 due to a lack 
Table 1.  ZIP synergy scores for conventional chemotherapeutic drugs or BER inhibitors in combination with 
TH5487.
Cell line Methotrexate Doxorubicin 5-Fluoracil APE1i PARPi Cisplatin
HCT116 10.77 4.97 5.33 3.55 3.09 2.84
NTUB1 48.56 5.84 − 3.09 3.05 3.28 − 14.97
U2OS 11.36 2.891 0.5 − 2.57 1.97 − 13.28
BJ-TERT 21 5.88 – – − 7.46 –
Figure 4.  Intracellular ROS formation. (A) Intracellular ROS (H2DCFDA mean intensity) generated after 
72 h of exposure to methotrexate (10 µM), alone or in combination with TH5487 (10 µM) in U2OS cells, (B) 
BJ-TERT, (C) NTUB1 or (D) HCT116 cells. 10 µM of TH5487 were used in combination with methotrexate 
for all the cell lines, except for NTUB1 where 5 µM of TH5487 were used. Data are average and SEM of single 
measurements from 2 independent experiments. Statistics were excluded from this analysis due to the low 
amount of data points to establish relevant comparisons between groups.
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of telomeric TRF2 foci detection by IF. In U2OS, TH5487 in combination with methotrexate caused a global 
effect (increased 53BP1/TRF2 overlapping index and increased micronuclei formation) greater than the sum 
of the individual effects of each drug, suggesting that TH5487 and methotrexate are synergistic drugs for these 
specific phenotypes (Fig. 5).
In the case of NTUB1 cell line, methotrexate increased significantly 53BP1 and TRF2 overlapping index, and 
TH5487 potentiated the effect of methotrexate in an additive manner, while micronuclei formation remained 
unchanged with any drug combination (Supplementary Figures S8A and S8B). In contrast, neither 53BP1 foci 
formation at telomeres nor micronuclei formation were detected in BJ-TERT cells after exposure to TH5487 or 
methotrexate alone or in combination (Supplementary Figures S8C and S8D).
Discussion
Telomeres and telomerase are key biological structures that facilitate cancer cell proliferation since cancer cells 
can bypass the lifespan limits of normal cells by overexpressing telomerase (Telomerase +), or by using the 
alternative lengthening of telomeres (ALT + cells). Hence, targeting telomeres or telomerase has been classically 
considered as a strategy for developing cancer  therapies7. In the present study, we have confirmed that TH5487 
blocks BER initiation at telomeres in response to OS, and we have characterized some of the TH5487 related 
telomeric and non-telomeric phenotypes in U2OS cells. Finally, we have tested different conventional chemo-
therapeutic agents in combination with TH5487, to identify potential synergistic drug combinations.
Even in basal conditions, we have found that telomeres are more prone to accumulate oxidative DNA dam-
age than other genomic regions, especially during the S and G2/M cell cycle phases (Fig. 1A and Figure S1C). 
This finding could be partially explained by, not only the progressive increase in intracellular ROS during the 
cell  cycle29,30, (Fig. 1D) but also by the high condensation degree of telomeric chromatin during most cell cycle 
 phases31,32, since OGG1 does not operate in single-stranded or G4  contexts16,33. In this regard, it has been recently 
Figure 5.  TH5487 synergizes with methotrexate through induction of telomere DNA damage, and genome 
instability. (A) Quantification of 53BP1 signal intensity integrated within telomeres from more than 200 U2OS 
cells per condition. Data are the average with SEM from 2 independent experiments. Significant differences 
were calculated using the Mann–Whitney test for non-parametric distributions (**** p < 0.0001 and ns: 
not significant). (B) Confocal imaging at single U2OS cells representative for each treatment condition and 
stained for 53BP1 (red) and TRF2 (green) using specific antibodies or DAPI to stain cell nucleus (blue). (C) 
Comparative analysis of micronuclei formation frequency for U2OS incubated with methotrexate (10 µM) for 
72 h, alone or in combination with TH5487 (10 µM) in U2OS cells. More than 200 cells per condition were 
analyzed. Data is the average of 2 independent experiments. Significant differences were calculated using the 
Mann–Whitney test for non-parametric distributions (** p < 0.01 and ns: not significant).
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reported that G4 folding occurs preferentially during G1/S and S-phases in U2OS  cells34. This correlates with the 
maximum peak in intracellular ROS formation and with the accumulation of oxidative DNA damage detected 
at both genomic and telomeric regions, which might support a cell cycle control of BER through the chromatin 
accessibility via G4 folding/unfolding.
We used  H2O2 to mimic OS conditions at  telomeres
35 and confirmed a significant increase in oxidative base 
lesions in the telomeric DNA (Supplementary Figure S3D). Interestingly, OGG1 protein levels did not increase 
in response to OS (Supplementary Figure S3A) and also remained constant throughout the cell cycle, reflecting 
that OGG1 expression is not cell-cycle regulated, or induced by oxidative DNA damage. However, we found that 
oxidative DNA damage accumulation at telomeres promoted the recruitment of BER enzymes to these regions 
to repair oxidized bases (Fig. 2). These results suggest that, although OGG1 might behave as a housekeeping 
 gene36,37, it is actively recruited at telomeres in response to oxidative DNA damage to initiate BER. Our results, 
together with previous studies, support the role of OGG1 as a key element promoting oxidative DNA damage 
repair at the telomere, via BER  initiation16,38–40.
Recently, the first example of a cell-active inhibitor targeting OGG1 has been  reported23 as well as details 
on how TH5487 binds to the human OGG1 sensitizing cancer cell lines by inducing replication stress without 
increasing nuclear 8-oxoG  levels24,25. In relation with this, the accumulation of 8-oxoG after TH5487 treatment 
could be expected at guanine enriched regions such as gene promoters, 5ʹ, and 3ʹ untranslated regions, or tel-
omeres. Indeed, here we have found several overlapping phenotypes between OGG1 depletion or inhibition in 
U2OS cells. First, a disruption in the recruitment of BER elements at telomeres during OS conditions was detected 
(Fig. 2), resulting in the accumulation of oxidized bases at this region (Supplementary Figure S4B). Although 
oxidative DNA lesions can potentially be converted into DSBs during  BER41, we were not able to detect telomere 
DNA damage response (DDR) because of OGG1 inactivation (Supplementary Figure S5). This result is supported 
by previous findings showing no DDR induction in OGG1 deficient  cells16, fewer incisions in TH5487-treated 
oxidatively stressed  cells24 or nor a DDR being restricted to cells undergoing replication after TH5487 treatment 
in leukemic  cells25. Second, we found that oxidative DNA damage at the telomere in OGG1 inactivated U2OS 
cells (depleted and/or TH5487-treated), correlated with telomere losses and micronuclei formation (Fig. 3B,D). 
In line with our results, these phenotypes were also reported in HeLa OGG1-KO cells in which chronic 8-oxoG 
at telomeres induced telomere replication stress resulting in telomere crisis and the arrest of cell  proliferation16.
In contrast, we detected minor proliferation defects related to OGG1 deficiency in combination with OS 
(Fig. 3E). Since some telomerase negative cells show high basal levels of signal-free ends and telomere sister 
chromatid  exchange42, which is characteristic of ALT + cancer cells, such as the U2OS cell  line43, it would be 
possible that telomere loss is well tolerated in these cells. And although we have recently proposed OGG1 as a 
potential anti-cancer target, and TH5487 targets a wide range of cancer  cells25, DepMap Public Database shows 
that cancer cell lines derived from bone, such as U2OS, present the lowest OGG1 cancer-dependency scores 
(DEMETER2; p = 6.3 ×  10–6) among lineages. On the other hand, it has been reported that TH5487 suppresses 
proinflammatory gene  expression23. Given that chronic inflammation leads to telomere  dysfunction44, the telo-
meric and post-mitotic defects caused by TH5487 could be attenuated by reducing the inflammatory conditions.
Finally, since TH5487 had a low impact on U2OS viability, we combined TH5487 with a heterogeneous set 
of conventional chemotherapeutic agents and BER inhibitors, looking for potential synergies in telomerase 
negative (U2OS) or positive transformed human cell lines (BJ-TERT, HCT116, NTUB1). Despite poly ADP 
ribose polymerase inhibitors (PARPi) targeting BER are known to induce replicative stress at telomeres that 
leads to telomere  crisis45, we did not find any synergy or additive effect with TH5487 (Table 1). Indeed, it has 
been recently described that olaparib toxicity in BRCA1-depleted cells is attenuated by treatments with a ROS 
scavenger, hypoxia, or OGG1  inhibitor46, suggesting that toxicity derived from PARPi in cancer cells might be 
attenuated by BER inhibition.
Among the different conventional cancer drugs tested, we found methotrexate to present the highest Zero 
Interaction Potency (ZIP) synergy scores (Z-score > 10 in the 4 tested cell lines). This drug has been reported to 
induce apoptosis through OS in rat small  intestine47, psoriasis  patients48, or lymphocytic T  cells49. In line with 
these findings, we showed that methotrexate induced intracellular ROS formation in all the cell lines we tested 
(Fig. 4). Although methotrexate and TH5487 consistently synergized and correlated with intracellular ROS for-
mation, the molecular mechanisms explaining the effects on cell viability for this drug combination were found 
to be cell type-specific and very little dependent on telomere instability or micronuclei formation in some cell 
lines, such as BJ-TERT, HCT116 or NTUB1.
On the other hand, we have reported that pharmacological inhibition of OGG1 with TH5487 might improve 
the anticancer properties of methotrexate in U2OS cells, partially through an additive or synergistic increase in 
telomere DNA damage (53BP1 overlapping with TRF2) and genome instability (micronuclei formation) (Fig. 5), 
which is potentially associated with methotrexate ROS induction. Supporting this, micronuclei formation in 
U2OS cells was found to increase upon OS especially in OGG1 inhibited/depleted U2OS (Fig. 5C). In contrast, 
telomere DNA damage in U2OS cells after combining TH5487 and methotrexate (Fig. 5A) might be independent 
of methotrexate ROS induction, since we did not find additive effects on 53BP1-TIF formation when combining 
TH5487 with  H2O2 (Supplementary Figure S5). Alternatively, this phenotype could be indirectly mediated by 
methotrexate folate  metabolism50 since methotrexate inhibits folic acid synthesis which has been reported to 
decrease intracellular ROS levels, telomeric DNA oxidative damage, and TIFs in  astrocytes51.
Combination therapies between TH5487 and methotrexate might be useful for those cancer types in 
which methotrexate is indicated such as breast cancer, acute lymphatic leukemia, lung cancer, lymphoma, and 
 osteosarcoma52. Besides cancer, there are some autoimmune diseases that are treated with methotrexate such 
as psoriasis, rheumatoid arthritis, and Crohn’s  disease52. Methotrexate in combination with tumor necrosis fac-
tor (TNF) inhibitors induces high remission rates in rheumatoid arthritis  patients53 or higher drug survival in 
psoriatic arthrosis  patients54. In this regard, TH5487 is also known to prevent tumor necrosis factor-α-induced 
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OGG1-DNA interactions that mediate TNF related pro-inflammatory gene  expression23. Hence, considering 
TH5487 as a “TNF-like inhibitor” we could expect some advantages of combination therapies in autoimmune 
diseases as well.
To conclude, our results show that TH5487 recapitulates some of the telomeric and post-mitotic defects 
previously reported in OGG1 KO  cells16. Therefore, OGG1 inhibitors can be considered as a new tool to block 
BER and to induce oxidative DNA damage at telomeres inducing cancer cell death, alone or in combination 
with other drugs like methotrexate. This combination could be especially interesting to overcome methotrex-
ate resistance in cancer or autoimmune  diseases55,56. In conclusion, our data not only illustrate the importance 
of BER in oxidative DNA damage repair at telomeres but also point to the possible use of the OGG1 inhibitor 
TH5487, alone or in combination with methotrexate, to induce telomere instability and proliferation defects, 
with potential implications in cancer treatment.
Methods
Cell culture and treatments. U2OS and BJ-TERT cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM; Lonza or Gibco) growth medium while NTUB1 and HCT116 were cultured in RPMI 1640 
(Gibco) and McCoy’s 5A Medium (Gibco), respectively. All cell lines were supplemented with 10% of fetal 
bovine serum (Biowest) and 100 U/ml penicillin–streptomycin (Gibco) and grew at 37 °C in a 5%  CO2 atmos-
phere. The U2OS human osteosarcoma cell line was obtained from the commercial supplier American Type 
Culture Collection (ATCC). The HCT116 human colon carcinoma cells were obtained from Dr. Bert Vogel-
stein (Johns Hopkins, Baltimore, MD). The NTUB1 human bladder carcinoma cells were obtained from Dr. TC 
Lee (Academia Sinica Taiwandisabled, Nankang, Taiwan). The BJ-Tert cell lines were provided by Dr. W. Hahn 
(Dana-Farber Cancer Institute).
To induce oxidative DNA damage, cells at about 80% of confluence were treated with  H2O2 (Sigma) at 200 µM 
in serum-free DMEM for the indicated periods. To perform OGG1 inhibition cells were released into fresh 
medium containing  TH548723 or DMSO (Sigma) for the indicated times and concentrations. After treatment, 
the cells were allowed to recover in complete growth medium for 1 h when mentioned. The different cell lines 
used for each experiment are detailed in Supplementary Table S1. Cell line authentication was performed by 
short tandem repeat (STR) Profiling, and mycoplasma testing was performed regularly.
Plasmid construction OGG1‑GFP and transfection. OGG1-GFP vector was generated according to 
the protocol described in Visnes et al.23. U2OS cells were transfected with the vector using jetPEI (Polyplus) and 
selected with 1 µg/ml puromycin for 10 days. This was followed by clonal expansion to generate a single clone 
of U2OS cells constitutively expressing OGG1-GFP, and thus variability in expression levels was minimized.
CRISPR/Cas9 knockout of OGG1. sgRNAs were designed using the Benchling CRISPR sgRNA Design 
tool (http://www.bench ling.com). A specific sgRNA was tested against OGG1 gene and also a non-targeting 
(NT) control was used (sgOGG1#1: GTG TAC TAG CGG ATC AAG TA and sgNT: CCG CGC CGT TAG GGA ACG 
AG). Those sequences were cloned into the lentiCRISPRv2 vector (Addgene plasmid #52961) and verified by 
Sanger sequencing.
Viruses were produced by transient plasmid transfection into 293 T cells by the calcium phosphate method, as 
previously  described57. Briefly, cells were seeded at 1.1 × 107 cells/dish in 15-cm dishes the day before transfection. 
U2OS OGG1-GFP cells were transfected using second-generation packaging plasmids (psPAX2 and pMD.2G, 
Addgene #12260 and #12259, respectively) and the appropriate transfer plasmid (pLV CRISPR sgOGG1 or sgNT). 
The medium was collected after 48 h, cleared by low-speed centrifugation, and filtered through 0.45 µm-pore-
size PVDF (polyvinylidene difluoride) filters (Millipore). Viral titers were calculated and values ranged around 
 107 to  108 TU/ml. In order to carry out transductions, cells were split and 24 h later were transduced using a 
multiplicity of infection (MOI) of 5 to ensure a high rate of transduced cells. Cells were incubated at 37 °C for 
12 h, and viral supernatant was replaced with fresh cell medium. A sorting step of the GFP-negative cells was 
carried out to finally obtain the pool of cells where OGG1 knockout was validated by immunoblotting and IF 
(further detailed protocol).
IF microscopy and image analysis. U2OS cells were seeded in a 12-well plate for 24 h before the start 
of the indicated treatments and followed by the IF protocol. Before fixation, cells were previously extracted 
with 0.2% Triton X-100 in PBS (phosphate buffered saline; Sigma) for 2 min (pre-extraction). Cells were fixed 
with 4% paraformaldehyde (PFA; Agar Scientific) for 10 min. After washing with PBS (Sigma), cell permea-
bilization was performed with 0.5% Triton X-100 (Sigma) in PBS for 15 min. Blocking with 3% bovine serum 
albumin (BSA; Sigma) in PBS for 1  h was followed by staining with primary and secondary antibodies and 
0.5 µg/ml 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Sigma). After each staining, a washing step 
three times (10  min in PBS each time). Primary antibodies used were mouse anti-TRF2 (ab13579, Abcam) 
at 1/200, with antirabbit anti-γH2AX (2577S; Cell Signalling), anti-53BP1 (ab36823, Abcam) at 1/1000, anti-
XRCC1(ab134056; Abcam) at 1/200. Secondary antibodies: Anti-mouse Alexa 555 (ThermoFisher Scientific), 
anti-rabbit Alexa 647 (ThermoFisher Scientific). All steps were performed at room temperature. Image acquisi-
tion was performed with a Leica confocal microscope SP5 using ACS APO 40.0 × 1.15 OIL lens. Image treat-
ment was done with Leica and ImageJ software and the analysis was performed using CellProfiler software. For 
the analysis, we evaluated mean signal intensity within telomeres for OGG1-GFP and XRCC1 as previously 
 described16 (BER activation at telomere). For DNA damage markers γH2AX and 53BP1, we measured overlap-
ping index with the telomere marker TRF2. Finally, micronuclei frequency was calculated using CellProfiler 
software. All the experiments were performed at least 2 independent times. Data is available.
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Telomere fluorescence in situ hybridization (Telo‑FISH). Cells were treated with 0.2 µg/ml Colce-
mide (Life Technologies) for 4 h to enrich cells at metaphase. Cell pellets were exposed to hypotonic treatment 
with 75 mM KCl solution, fixed in cold Carnoy’s solution [methanol:acetic acid (3:1)], and spread onto glass 
slides. The samples were fixed again in PBS containing 3.7% PFA and dehydrated by successive incubations in 70, 
80, and 100% ethanol before FISH hybridization. DNA was denatured at 72 °C in 1 M HCl, 20 × saline-sodium 
citrate (SSC), and deionized formamide hybridization mixture, and hybridized with Cy3-labeled (CCC TAA 
)3 peptide nucleic acid (PNA) telomere probe (0.5 μg/ml) [Panagene, PNA BIO/F1001 (TelC-FAM)]. Finally, 
the slides were washed with a buffer containing the same high percentage of formamide to remove the non-
specifically bound probe, and DNA was stained with 0.5 µg/ml DAPI/Antifade solution (Palex Medical). Telo-
FISH images were digitally acquired with a CCD camera (Photometrics SenSys) connected to a Leica DM5500B 
microscope using a 100 × objective and using CytoVision software 7.2. Images were blindly analyzed to score for 
chromosome multi-telomeric signal or signal-free ends.
Cell sorting. U2OS cells were trypsinized, resuspended at a concentration of 5 × 106 cells/ml and incubated 
with 5 µg/ml Hoechst for 15 min at 37 °C in the dark. Cells were sorted based on the amount of DNA by defining 
three regions for sorting: G1, S, and G2/M phases. A post-sorting purity check was used to confirm the purities 
of the resulting sorted populations that were higher than 90% in all cases (Supplementary Figure S1A). The sort-
ing was performed with the use of a BD Influx (BD Biosciences). The separated cells (at least 1 × 106 cells from 
each sorted population) were collected in tubes containing 0.5 ml culture medium and after centrifugation, cell 
pellets were stored at − 20 °C until used for DNA or protein extraction.
Colony formation assay. U2OS cells (OGG1-GFP or OGG1-KO) with DMSO or with the indicated con-
centration of TH5487 were counted and seeded on 10 cm Petri dishes (500 cells per dish) and incubated until 
colony size surpassed a minimum of 50 cells (6 days). Then, the medium was removed, and cells were challenged 
with a single pulse of OS  H2O2 (Sigma) at 200 µM in serum-free DMEM for 1 h). Next, treatment was removed, 
and cells were plated in complete medium in the presence or absence of TH5487 (10 µM) for 6 additional days. 
Finally, cells were washed twice with PBS, fixed with ice-cold methanol (Sigma) for 5 min, and stained with 1% 
crystal violet solution (Sigma) for 30 min. Following extensive washes in tap water and air drying. Plates were 
scanned and relative colony area was measured with ImageJ software. This experiment was performed once. 
Data is available.
DNA extraction, human OGG1 purification and relative quantification of oxidized bases in 
specific genome regions by quantitative PCR (qPCR). DNA was extracted from cultured cells using 
the Flexigene DNA Kit (Qiagen) following the manufacturer’s instructions and quantified by the PicoGreen 
fluorometric assay (Thermo Fisher Scientific).
We have adapted the telomere oxidation protocol previously  described27 to quantify the relative accumulation 
of oxidized bases in specific genome regions by incubating the DNA with hOGG1 protein, which was previously 
purified as previously  reported23. This is a qPCR method which is based on differences in PCR kinetics between 
template DNA digested by OGG1 and undigested DNA. This enzyme recognizes and cuts 8-oxoG, producing 
abasic sites that are converted into SSBs by its AP lyase activity. These SSBs inhibit the PCR, thus, the ΔCt after 
digesting DNA by OGG1 (Ct digested–Ct undigested) is proportional to the oxidative damage in the ampli-
fied region (Supplementary Figure S1B). Conditions used for incubation were 2.4 μM hOGG1 for 4 h in DNA 
glycosylase buffer (25 mM Tris–HCl, 15 mM NaCl, 2 mM  MgCl2, 0.0025% Tween-20 at pH = 8). The reaction 
was stopped by incubating at 95 °C for 5 min. qPCR analysis was performed on 40 ng of digested or undigested 
genomic DNA using the same reagents, primers, and conditions as described in the original  protocol27. Each 
qPCR was performed in triplicate including no-template controls in an Abi QuantStudio 6 Flex Real-Time PCR 
System (Applied Biosystems). Primers used are listed in Supplementary Table S2. Six independent experiments 
were included for each condition and analyzed in triplicate. Data is available.
Protein extraction, quantification, and immunoblotting. Protein expression was determined by 
immunoblotting. Briefly, cell pellets were prepared in radioimmunoprecipitation assay (RIPA) buffer (Sigma) 
in the presence of a protease inhibitor cocktail (Roche). Total protein concentration was determined using 
the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. Forty 
micrograms of protein were electrophoresed on 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to Immobilon-FL membranes (Millipore). Membranes were blocked in tris buff-
ered saline with Tween-20 (TBS-T; 50 mM Tris/HCl, 150 mM NaCl, pH 7.5 plus 0.2% Tween-20) and 5% non-fat 
milk for 1 h at room temperature. Blots were probed with the following primary antibodies: rabbit anti-OGG1 
(ab124741, Abcam) at 1/2500 dilution, and mouse anti-β-actin (A5441; Sigma) at 1/10,000 dilution in TBS-T 
containing 5% non-fat milk. Anti-mouse and anti-rabbit IgG-HRP (immunoglobulin G horseradish peroxidase; 
Dako) were used as the secondary antibodies, and the immunoblots were developed using Immobilon Classico 
Western HRP substrate (Millipore). Each immunoblot was performed in triplicate. Images were analyzed using 
ImageJ software (NIH Image), and OGG1 protein level was normalized to actin levels. The full-length blots are 
presented in Supplementary Figure S2.
Detection of intracellular ROS during cell cycle phases by flow cytometry. The generation of 
intracellular ROS during the cell cycle was determined using the fluorescent probe 2′,7′-dichlorodihydrofluores-
cein diacetate (H2DCFDA; Molecular Probes) combined with Hoechst staining for detecting DNA content. The 
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non-fluorescent H2DCFDA passively diffuses into cells and is converted to the highly fluorescent 2′,7′-dichloro-
fluorescein (DCF) upon oxidation by ROS. Cells were harvested using Trypsin (1×) for 5 min, pelleted and 
resuspended in PBS containing Hoechst (1 µg/ml) for 15 min. Then, cells were washed with PBS and pelleted by 
centrifugation. Next, pellets were resuspended in RPMI without serum-containing H2DCFDA to a final con-
centration of 10 μM, cells were incubated for 30 min at 37 °C and analyzed by flow cytometry (Navios, Beckman 
Coulter) using the FL1 (525/540 nm) or FL9 (450/460 nm) channels. We used the median value of H2DCFDA 
intensity as a threshold to stratify negative (below median) or positive (above median) cells. Then, the percentage 
of ROS positive cells in G1, S, or G2M phases was calculated. This experiment was performed two independent 
times. Data is available.
Chromatin immunoprecipitation (ChIP). ChIP was performed as previously  reported58 in parental 
U2OS cells or U2OS OGG1-GFP cells. Chromatinized OGG1-GFP protein fraction was enriched by using GFP-
Trap for immunoprecipitation (Chromotek). DNA bound to OGG1-GFP was heated to reverse crosslinking. The 
purified OGG1-GFP DNA was amplified by PCR both telomere sequence and the single-copy gene 36B4 using 
specific primers (Supplementary Table S2). OGG1-GFP enrichment at telomeres or 36B4 normalized to the 10% 
input was used to calculate the relative OGG1 enrichment for the 2 regions in U2OS-GFP cells compared to the 
parental U2OS cells. This experiment was performed 2 times. Data is available.
OGG1 target engagement. For sample preparation, cells were incubated with 20 µM TH5487 for 2 h at 
37 °C, before they were submitted for 3 min at twelve different temperatures ranging from 37 to 62 °C. After the 
addition of lysis buffer [50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 
1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS supplemented with complete protease inhibitor cocktail 
(Roche)], cell lysis by freezing–thawing took place. In the following centrifugation (30 min at 17,000g at 4 °C) 
was performed and 70 µL of the supernatant was mixed with 23 µL loading dye before the samples were heated 
at 95 °C for 10 min. In the following, SDS-PAGE and WB were performed. The membrane was blocked with 
5% skimmed milk for 1 h at room temperature. As primary antibodies rabbit anti-OGG1 (ab124741, Abcam) 
1:1,000 and mouse anti-Actin (ab6276, Abcam) 1:5,000 were used. This experiment was performed once in 
U2OS cells (parental) and once in U2OS OGG1-GFP cells (not shown). Data is available.
Synergy experiments. Drug combinations were built and dispensed using D300e Digital Dispenser 
(Tecan) in 96 or 384 well plates. Cells were seeded in 96- or 384-well plates containing drug combinations by 
using Multidrop Combi Reagent Dispenser (ThermoFisher Scientific). Then, cells were incubated for 3 days at 
37 °C. Resazurin (R7017, Sigma) was added to a final concentration of 0.01 mg/ml resazurin and fluorescence 
was measured at ex530/em590 after incubation for 6 h in an Hidex Sense microplate reader (Hidex). Drug syn-
ergy Z-score was calculated and interpreted using Synergy Finder (http://syner gyfin der.fimm.fi).
A preliminary synergy screening in U2OS, BJ-TERT, NTUB1, and HCT116 cells for TH5487 with conven-
tional chemotherapeutic drugs (cisplatin, 5-Fluoracil, doxorubicin, methotrexate) or BER inhibitors (olaparib, 
APE1i) was initiated to select the candidates. This initial screening was performed once. For the best candidates, 
methotrexate and doxorubicin synergies were repeated three independent times in four independent cell lines 
(U2OS, BJ-TERT, HCT116 and NTUB1).
Statistical analysis. The Kolmogorov–Smirnov test was used to evaluate whether the data sets were nor-
mally distributed. For comparative analyses, statistically significant differences were assessed by an unpaired 
t-test for normal distributions and the Mann–Whitney U-test for non-normal distributions. Statistical calcula-
tions and graphs were done using the SPSS software package version 19.0 (IBM) and GraphPad Prism 8 (Graph-
Pad Software Inc).
Data availability
The datasets used and analysed during the current study are available from the corresponding author upon 
reasonable request.
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